Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi

Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi

In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of care for patients with symptomatic advanced disease. More recently, the combination of bendamustine plus rituximab (R-B)...

Full description

Bibliographic Details
Main Authors: Gloria Margiotta-Casaluci, Sara Bigliardi, Federica Cocito, Erika Meli, Luigi Petrucci, Maura Nicolosi, Ombretta Annibali, Carola Boccomini, Valentina Bozzoli, Alessia Castellino, Federica Cattina, Natalia Cenfra, Sabino Ciavarella, Sofya Kovalchuk, Francesco Rotondo, Angelo Fama, Jacopo Olivieri, Francesco Zaja
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
follicular lymphoma
grade 3A
bendamustine
CHOP
rituximab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1120967/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1120967/full

Similar Items